Metabolic Disorders
GlobalData’s reports offer expert analysis, insights and opinions to companies in the world’s largest industries. Explore unique market-leading data today and benefit from access to actionable insight within the Metabolic Disorders market. Reports cover market growth forecasts, trends and research, and more.
Browse our full list of Metabolic Disorders market reports here.
- Currency Conversion is for Indicative purpose only. All orders are processed in US Dollars only.
- USD - US Dollar
- AUD — Australian Dollar
- BRL — Brazilian Real
- CNY — Yuan Renminbi
- EUR — Euro
- GBP — Pound Sterling
- INR — Indian Rupee
- JPY — Japanese Yen
- ZAR — South African Rand
- The Price Conversion is only for the Indicative purpose.
- USD — US Dollar
- AUD — Australian Dollar
- BRL — Brazilian Real
- CNY — Yuan Renminbi
- EUR — Euro
- GBP — Pound Sterling
- INR — Indian Rupee
- JPY — Japanese Yen
- ZAR — South African Rand
-
Sector Analysis
Hyperparathyroidism, Hyperphosphatemia, and Hyperkalemia in Chronic Kidney Disease: Opportunity Assessment, Epidemiology, Disease Management, and Forecast to 2034 Hyperparathyroidism, Hyperphosphatemia, and Hyperkalemia in Chronic Kidney Disease: Opportunity Assessment, Epidemiology, Disease Management, and Forecast to 2034
$17,995 | November 2025 This report covers the 7MM (US, 5EU, Japan) and provides an Excel-based forecast model for the CKD-HPT, HP and HK market through 2034. • There will be an overall increase in the diagnosed prevalent cases of CKD- HPT, HP and HK in the 7MM across the forecast period. • Across the 7MM, the mainstay treatment for HPT, HP, and HK involves phosphate binders, calcimimetics, and potassium binders • Significant clinical and environmental unmet needs remain in the CKD- HPT, HP...
-
Sector Analysis
Hypoglycemia Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape Hypoglycemia Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
$3,495 | October 2025 This reports provides a data-driven overview of the current and future competitive landscape in Hypoglycemia Therapeutics. • In 2024 and 2029, India is estimated to have the highest number of diagnosed incident cases of hypoglycemia, representing a large portion of global cases. • Novo Nordisk’s GlucaGen (glucagon hypokit) and Eli Lilly’s Glucagon had been the primary marketed glucagons for decades. • The hypoglycemia pipeline holds 16 molecules, with no assets in the pre-registration stage, three assets in Phase III development,...
-
Sector Analysis
Diabetic Retinopathy Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape Diabetic Retinopathy Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
$3,495 | October 2025 This reports provides a data-driven overview of the current and future competitive landscape in Diabetic Retinopathy Therapeutics. • In 2024, there were more than 46 million ldiagnosed prevalent cases of DR in the 16 countries covered in GlobalData’s epidemiology forecast. • Currently, the DR market is saturated with generic drugs, and the platelet activating factor (PAF) inhibitor drug class dominates the approved innovator drugs currently available to treat DR. • The DR pipeline holds 140 molecules, with three assets in...
-
Product Insights
Overweight: Global Clinical Trials Review, 2025 Overweight: Global Clinical Trials Review, 2025
$3,450 | September 2025 GlobalData's clinical trial report, “Overweight - Global Clinical Trials Review, 2025" provides an overview of Overweight Clinical trials scenario. This report provides top line data relating to the clinical trials on Overweight. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Amyloidosis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update Amyloidosis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
$3,450 | August 2025 GlobalData's clinical trial report, “Amyloidosis - Global Clinical Trials Review, 2025" provides an overview of Amyloidosis Clinical trials scenario. This report provides top line data relating to the clinical trials on Amyloidosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Hyperglycemia Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update Hyperglycemia Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
$3,450 | August 2025 GlobalData's clinical trial report, “Hyperglycemia - Global Clinical Trials Review, 2025" provides an overview of Hyperglycemia Clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperglycemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Hypoglycemia Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update Hypoglycemia Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
$3,450 | May 2025 GlobalData's clinical trial report, “Hypoglycemia - Global Clinical Trials Review, 2025" provides an overview of Hypoglycemia Clinical trials scenario. This report provides top line data relating to the clinical trials on Hypoglycemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Sector Analysis
Phenylketonuria Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape Phenylketonuria Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
$3,495 | March 2025 This reports provides a data-driven overview of the current and future competitive landscape in Phenylketonuria Therapeutics. - GlobalData epidemiologists estimate that there were 498,757 diagnosed prevalent cases of Phenylketonuria in 2024, which is expected to increase slightly to 557,730 diagnosed prevalent cases by 2029. - PKU is managed through a combination of supportive care, chemotherapy, and targeted therapies. - The PKU pipeline holds 262 molecules, with two assets in the pre-registration stage, 16 assets in Phase III development, and 87...
-
Product Insights
Type 1 Diabetes (Juvenile Diabetes) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update Type 1 Diabetes (Juvenile Diabetes) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
$3,450 | March 2025 GlobalData's clinical trial report, “Type 1 Diabetes (Juvenile Diabetes) - Global Clinical Trials Review, 2025" provides an overview of Type 1 Diabetes (Juvenile Diabetes) Clinical trials scenario. This report provides top line data relating to the clinical trials on Type 1 Diabetes (Juvenile Diabetes). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...
-
Product Insights
Diabetic Macular Edema Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update Diabetic Macular Edema Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
$3,450 | February 2025 GlobalData's clinical trial report, “Diabetic Macular Edema - Global Clinical Trials Review, 2025" provides an overview of Diabetic Macular Edema Clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Macular Edema. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.